36 completed, 15 recruiting, 15 terminated, 10 unknown. 48 Phase 2, 29 Phase 1, 9 Not applicable, 9 Phase 3, 3 Early Phase 1.
Follow Hematopoietic Stem Cell Transplantation: new trials by email Literature Review of Hematopoietic Stem Cell Transplantation trials Research Report on Hematopoietic Stem Cell Transplantation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Biospecimen Collection, Busulfan, Computed Tomography - Acute Myeloid Leukemia, Graft Versus Host Disease | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2026-06-12 | 2026-07-01 |
| Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia VDCLP+V, 2VIP, Consolidation Therapy - Acute Lymphoblastic Leukemia, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 43 | 2026-04-08 | 2026-08-10 |
| Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation Ruxolitinib, Myeloablative conditioning regimen, Hematopoietic Stem Cell Transplantation - Leukemia, Myelodysplasia | Phase 2 | Recruiting | Hannah Choe, MD | 124 | 2026-01-14 | 2026-09-02 |
| Prehabilitation for Patients Diagnosed With Blood Cancer and Treated With Al-logeneic Hematopoietic Stem Cell Transplantation Resistance training, Nutritional Support, Usual care - Allogeneic Hematopoietic Stem Cell Transplantation Recipient | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 110 | 2026-01-12 | 2026-01-29 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Actinium Ac 225-DOTA-Daratumumab, Biospecimen Collection, Bone Marrow Aspiration - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Recruiting | City of Hope Medical Center | 15 | 2025-07-01 | 2026-07-31 |
| Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Biospecimen Collection, Chest Computed Tomography, Echocardiography - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | City of Hope Medical Center | 40 | 2024-08-01 | 2026-10-14 |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Ganglioneuroblastoma, Nodular, Neuroblastoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 478 | 2024-04-19 | 2026-10-26 |
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia Clofarabine, Fludarabine, Hematopoietic Cell Transplantation - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 23 | 2023-08-11 | 2026-08-06 |
| TMLI and Alemtuzumab for Treatment of Sickle Cell Disease Alemtuzumab, Hematopoietic Cell Transplantation, Intensity-Modulated Radiation Therapy - Sickle Cell Disease | Phase 1 | Active not recruiting | City of Hope Medical Center | 20 | 2022-07-13 | 2026-07-30 |
| Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab - Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Recruiting | Emory University | 46 | 2022-05-02 | 2026-09-08 |
| A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia Hematopoietic stem cell transplantation, Best chemotherapy treatment - Acute Myeloid Leukemia | Not applicable | Active not recruiting | Assistance Publique - Hôpitaux de Paris | 24 | 2021-12-31 | 2025-08-13 |
| Two Step Haplo With Radiation Conditioning Fludarabine, Total-Body Irradiation, Donor Lymphocyte Infusion - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | Thomas Jefferson University | 63 | 2021-10-25 | 2025-10-30 |
| Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Busulfan, Cladribine, Fludarabine Phosphate - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 / Phase 3 | Recruiting | M.D. Anderson Cancer Center | 324 | 2021-10-21 | 2026-08-11 |
| Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021) the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors. - Acute Lymphoblastic Leukemia, Pediatric, ALL, Infants | Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 80 | 2021-09-23 | 2024-06-28 |
| BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 49 | 2021-02-17 | 2026-06-12 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia Cladribine, Cyclophosphamide, Cyclosporine - Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 120 | 2020-12-03 | 2026-09-17 |
| Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation Melphalan - Hematopoietic Stem Cell Transplantation | Phase 1 | Unknown | Seoul National University Hospital | 20 | 2020-09-11 | 2023-02-06 |
Showing 20 of 88. Sign in to see all of them.
Leukemia, Myeloid, Acute (19) · Myelodysplastic Syndromes (15) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (14) · Multiple Myeloma (9) · Anemia, Sickle Cell (8) · Hematologic Neoplasms (8) · Leukemia (8) · Graft vs Host Disease (7) · Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma (7) · Hodgkin Disease (6) · Leukemia, Myelomonocytic, Chronic (6) · Lymphoma, Non-Hodgkin (6) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Follicular (5)
City of Hope Medical Center (9) · Masonic Cancer Center, University of Minnesota (7) · Northwestern University (7) · M.D. Anderson Cancer Center (6) · Fred Hutchinson Cancer Center (5) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (5) · St. Jude Children's Research Hospital (4) · Richard Burt, MD (3) · Azienda Ospedaliera San Giovanni Battista (2) · Emory University (2) · National Cancer Institute (NCI) (2) · Acrotech Biopharma Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · CANDONI ANNA (1) · Centre Oscar Lambret (1)
United States (60) · Italy (5) · France (4) · China (3) · Mexico (2) · South Korea (2) · Australia (1) · Canada (1) · Denmark (1) · Germany (1) · Japan (1) · New Zealand (1) · Puerto Rico (1) · Russia (1) · Switzerland (1)
Richard Burt, MD (10) · Daniel J. Weisdorf, MD (2) · Dolores Grosso, DNP, CRNP (2) · Neal Flomenberg, MD (2) · Phuong Vo (2) · Alessandra Maestro, PharmD, PhD (1) · Amandeep Salhotra (1) · Amer M Zeidan (1) · Amin Alousi, MD (1) · Anna B. Pawlowska, MD (1) · Anna Pawlowska (1) · Anne Sophie Defachelles, MD (1) · Bayard Powell (1) · Benedetto Bruno, MD, PhD (1) · Brandon Triplett, MD (1)
PMID 12171484, PMID 17360989, PMID 19064724, PMID 20837778, PMID 21586746, PMID 22282904, PMID 23074282, PMID 23416852, PMID 26348869, PMID 26367236, PMID 27625358, PMID 28514773, PMID 29788474, PMID 31188727, PMID 31394007, PMID 31400502, PMID 31612640, PMID 32499241, PMID 32594300, PMID 32683126, PMID 34156440, PMID 34813516, PMID 35354808, PMID 36240296, PMID 37574821, PMID 37866669, PMID 37877375, PMID 38177042, PMID 38230519, PMID 38291722, PMID 38446568, PMID 39121442, PMID 39316653, PMID 40908865, PMID 42053946
P30CA033572 (5), P30CA015704 (2), 2009 (1), F32CA141762 (1), P01HL122173 (1), P30CA012197 (1), P30CA016672 (1), P30CA021765 (1), P30CA138292 (1), R37CA036401 (1), U01HL068091 (1), U01HL069294 (1), U10CA180886 (1), U24CA076518 (1), UM1CA186689 (1)